Harrow (HROW) Q1 2025 Earnings Call May 09, 2025 08:00 AM ET Speaker0 Good morning, and welcome to Harrow's First Quarter twenty twenty five Earnings Conference Call. My name is Shannon, and I will be your operator for today's call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session. As a reminder, this conference is being recorded. I would now like to turn the call over to Jamie Webb, Director of Communications and Investor Relations for Harrow. S ...

Harrow (HROW) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -2,000%. A quarter ago, it was expected that this pharmaceutical and drug compounding company would post earnings of $0.11 per share when it actually produced earnings of $0.25, delivering a surprise of 127.27%.Over the last four quarters, t ...

Investor Presentation | May 2025 Safe Harbor This presentation contains "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Harrow, Inc. (the "Compan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the quarterly period ended March 31, 2025 Washington, D.C. 20549 or FORM 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _____________ Commission File Number: 001-35814 Harrow, Inc. (Exact name of registrant as specified in its charter) Delaware 45-0567010 (State or other ju ...

Exhibit 99.2 Letter to Stockholders May 8, 2025 Dear Harrow Stockholders: Today, we reported first-quarter 2025 revenues of $47.8 million, a 38% increase over the prior-year's first-quarter revenues of $34.6 million and, as expected, a sequential decrease from fourth-quarter 2024 revenues. In addition to record-high cash flow from operations of $19.7 million for the quarter, a very bright spot was VEVYE, as revenues rose 35% quarter-over-quarter, increasing from $16.0 million in the fourth quarter of 2024 t ...

BERWYN, Pa., April 24, 2025 /PRNewswire/ -- Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., announced a partnership with Harrow (Nasdaq: HROW), a leading North American eyecare company, to launch an authorized generic of Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension), which treats and relieves bacterial eye infections. Maxitrol® and generic equivalents had annual sales of $20.8 million in the U.S., according to IQVIA data, as of January 2025. "Today marks the c ...

Harrow (HROW) Q4 2024 Earnings Call March 28, 2025 03:29 PM ET Company Participants Jamie Webb - Director of Communications & Investor RelationsMark Baum - Chief Executive Officer and Chairman of the BoardAndrew Boll - CFO & Corporate SecretaryJeffrey Cohen - MD - Equity ResearchMayank Mamtani - Senior Managing DirectorYi Chen - Managing Director, Equity Research Conference Call Participants Chase Knickerbocker - Senior Equity Research Analyst - HealthcareThomas Flaten - Senior Research Analyst Operator Goo ...

Core Viewpoint - Harrow, Inc. is conducting its Q4 2024 earnings conference call, indicating a focus on financial performance and future outlook [1][3]. Group 1: Company Overview - Harrow, Inc. is listed on NASDAQ under the ticker HROW [1]. - The earnings conference call is scheduled for March 28, 2025, at 8:00 AM ET [1]. Group 2: Participants - The call features key company participants including Jamie Webb (Director of Communications & IR), Mark Baum (CEO), and Andrew Boll (CFO) [1]. - Various analysts from firms such as Craig Hallum, Lake Street Capital Markets, and B. Riley Securities are participating in the Q&A session [1]. Group 3: Forward-Looking Statements - The company’s remarks may include forward-looking statements, which are subject to risks and uncertainties beyond Harrow's control [3]. - Risks include the ability to commercially launch FDA-approved products and the timely approval of certain drug candidates [3].

Group 1 - Harrow, Inc. (NASDAQ: HROW) has been identified as a speculative trade opportunity after experiencing a selloff, previously noted in the high $30s range [2] - The investment strategy emphasizes a blended approach of trading and income generation, aiming to enhance savings and retirement timelines [1] - The investment group, BAD BEAT Investing, has a proven track record, including a notable call to sell everything and go short in February 2020, maintaining an average position of 95% long and 5% short since May 2020 [2] Group 2 - BAD BEAT Investing focuses on short- and medium-term investments, income generation, special situations, and momentum trades, providing in-depth research with clear entry and exit targets [2] - The team consists of seven analysts with diverse expertise in business, policy, economics, mathematics, game theory, and sciences, sharing both long and short trade ideas [2]

Investor Presentation | March 2025 Safe Harbor This presentation contains "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Harrow, Inc. (the "Comp ...